Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
West Penn Allegheny Health System
With
Aventis Pharmaceuticals
Age
6–13
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male/Female aged 6-13 years of age
Diagnosis of SAR/PAR, with symptoms within the past 3 months
Positive skin test to inhalant allergen with negative saline control
No previous use of intranasal inhaled, oral, IV or topical steroid use within past 6 months.
If the subject has asthma, only mild intermittent (per NAPP) guidelines treated with PRN bronchodilator
You may not be if
screening height outside the 5th and 95th percentiles
History of abnormal growth
Any other chronic condition beside allergic rhinitis or mild intermittent asthma
Subject who has insufficient allergic rhinitis symptoms to require daily therapy during the trial.
Subject with a known hypersensitivity to any active ingredients or excipents in the study medications
Subject with nasal candidiasis, acute or chronic sinusitis, significant nasal polyposis (impairs nasal breathing), or other gross anatomical deformity of the nose sufficient to impair nasal breathing (e.g., deviated septum)
Subjects with a history of substance abuse, mental illness or retardation
Subjects with a history or presence of glaucoma or posterior subcapsular cataract
Subjects with nocturnal enuresis.
Use of Theophylline, Intal/Tilade or leukotriene modifiers.
Clareo Health | Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis
